INTEGRATED RESEARCH LIMITED — Capital/Financing Update 2018

Dec 19, 2018

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

INTEGRATED RESEARCH LIMITED

ABN

76 003 588 449

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of+securities issued or to be issued 2 Number of+securities issued or to be issued (if known) or maximum number which may be issued 3 Principal terms of the+securities (e.g. if options, exercise price and expiry date; if partly paid+securities, the amount outstanding and due dates for payment; if+convertible securities, the conversion price and dates for conversion)	N/A
	194,750 performance rights
	New Performance Rights issued in accordance with the terms of the Integrated Research Performance Rights and Option Plan. (new class) Exercise Price: $0.00 Expiry Date: 31 October 2021 194,750 new performance rights subject to service criteria.

• See chapter 19 for defined terms.

04/03/2013

Appendix 3B Page 1

4 Do the+securities rank equally in all respects from the+issue date with an existing+class of quoted+securities? If the additional+securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 5 Issue price or consideration 6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) 6a Is the entity an+eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h_in_ relation to the+securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder resolution under rule 7.1A was passed 6c Number of+securities issued without security holder approval under rule 7.1 6d Number of+securities issued with security holder approval under rule 7.1A 6e Number of+securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A
	N/A
	Issued under the terms and conditions of the Integrated Research Performance Rights and Option Plan.
	No
	N/A
	N/A
	N/A
	N/A

6f Number of+securities issued under an exception in rule 7.2 6g If+securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the+issue date and both values. Include the source of the VWAP calculation. 6h If+securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements 6i Calculate the entity’s remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements 7 +Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B. 8 Number and+class of all+securities quoted on ASX (_including_the +securities in section 2 if applicable)	N/A
	N/A
	N/A
	N/A
	18 December 2018
	Number	+Class
	171,770,753	Ordinary Shares

• See chapter 19 for defined terms.

04/03/2013

Appendix 3B Page 3

Number +Class 9 Number and+class of all+securities not quoted on ASX (including the +securities in section 2 if applicable) 90,000 Note: Employee Performance Rights - IRIAT Nil Note: 60,000 IRIAW Employee Performance Rights previously issued have been cancelled. Employee Performance Rights - IRIAW 110,000 Note: Employee Performance Rights - IRIAA 210,000 Note: Employee Performance Rights - IRIAA 366,000 Note: 34,000 IRIAZ Employee Performance Rights previously issued have been cancelled. Employee Performance Rights - IRIAZ 120,000 Note: Employee Performance Rights - IRIAAA 194,750 Note: New Class of Employee Performance Rights issued Employee Performance Rights 10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests) N/A Part 2 - Pro rata issue 11 Is security holder approval required? 12 Is the issue renounceable or non- renounceable? 13 Ratio in which the+securities will be offered 14 +Class of+securities to which the offer relates 15 +Record date to determine entitlements 16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements? 17 Policy for deciding entitlements in relation to fractions	Number	Number	+Class
	90,000 Note:		Employee Performance Rights - IRIAT
	Nil Note: 60,000 IRIAW Employee Performance Rights previously issued have been cancelled.		Employee Performance Rights - IRIAW
	110,000 Note:		Employee Performance Rights - IRIAA
	210,000 Note:		Employee Performance Rights - IRIAA
	366,000 Note: 34,000 IRIAZ Employee Performance Rights previously issued have been cancelled.		Employee Performance Rights - IRIAZ
	120,000 Note:		Employee Performance Rights - IRIAAA
	194,750 Note: New Class of Employee Performance Rights issued		Employee Performance Rights
	N/A

• See chapter 19 for defined terms.

Appendix 3B Page 4

04/03/2013

18	Names of countries in which the entity has	Names of countries in which the entity has
	security holders who will not be sent new
	offer documents
	Note: Security holders must be told how their entitlements are to
	be dealt with.
	Cross reference: rule 7.7.
19	Closing date for receipt of acceptances	or
	renunciations
20	Names of any underwriters
21	Amount of any underwriting fee	or
	commission
22	Names of any brokers to the issue
23	Fee or commission payable to the broker	to
	the issue
24	Amount of any handling fee payable	to
	brokers who lodge acceptances	or
	renunciations on behalf of security holders
25	If the issue is contingent on security holders’
	approval, the date of the meeting
26	Date entitlement and acceptance form and
	offer documents will be sent to persons
	entitled
27	If the entity has issued options, and the terms
	entitle option holders to participate	on
	exercise, the date on which notices will	be
	sent to option holders
28	Date rights trading will begin (if applicable)
29	Date rights trading will end (if applicable)
30	How do security holders sell their
	entitlements_in full_through a broker?
31	How do security holders sell_part_of their
	entitlements through a broker and accept for
	the balance?

• See chapter 19 for defined terms.

04/03/2013

Appendix 3B Page 5

• 32 How do security holders dispose of their entitlements (except by sale through a broker)?

• 33 +Issue date

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

• 34 Type of[+] securities ( tick one )

• (a) +Securities described in Part 1 (b)[All other ][+][securities ]

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35 If the[+] securities are[+] equity securities, the names of the 20 largest holders of the additional[+] securities, and the number and percentage of additional[+] securities held by those holders

36 If the[+] securities are[+] equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over 37 A copy of any trust deed for the additional[+] securities

• See chapter 19 for defined terms.

Appendix 3B Page 6

04/03/2013

Entities that have ticked box 34(b)

Entities that have ticked box 34(b)
38 Number of+securities for which+quotation is sought 39 +Class of+securities for which quotation is sought 40 Do the+securities rank equally in all respects from the+issue date with an existing+class of quoted+securities? If the additional+securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 41 Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another+security, clearly identify that other+security) 42 Number and+class of all+securities quoted on ASX (_including_the+securities in clause 38)
	Number	+Class

• See chapter 19 for defined terms.

04/03/2013

Appendix 3B Page 7

Quotation agreement

• 1 +Quotation of our additional +securities is in ASX’s absolute discretion. ASX may quote the[+] securities on any conditions it decides.

• 2 We warrant the following to ASX.

• The issue of the[+] securities to be quoted complies with the law and is not for an illegal purpose.

• There is no reason why those[+] securities should not be granted[+] quotation.

• An offer of the[+] securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

• Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any[+] securities to be quoted and that no-one has any right to return any[+] securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.

• If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the[+] securities be quoted.

• 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

• 4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

==> picture [119 x 38] intentionally omitted <==

Sign here: ........................................................ Date: 20[th] December 2018 (Company Secretary)

Print name: David C Purdue

== == == == ==

• See chapter 19 for defined terms.

Appendix 3B Page 8

04/03/2013